Floatz logo

Epirubicin

Residual Disease

Dartmouth-Hitchcock Medical CenterPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the Residual Disease cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
University of Chicago
Phase 2B
cc-5013
University of Chicago
Phase 2B
mln9708
University of Chicago
Phase 2B
Datopotamab Deruxtecan
UNC Lineberger Comprehensive Cancer Center
Phase 2CCC
Wokvac Vaccine
H. Lee Moffitt Cancer Center and Research Institute
Phase 2CCC

View all 13 →

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Lung Non-Small Cell Squamous CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →